

AGENDA

Blood Cancers and CLL on the European Agenda: From Recognition to Action

Launch of ECLLA's European Policy Brief during Blood Cancer Awareness Month

Event details

Date	30 September 2026
Time	10:00 – 12:00 (Programme 10:00–11:30, Q&A Networking 11:30–12:00)
Format	In-person – hybrid/streaming
Location	Hub space, European Parliament, Brussels
Host	MEP Regina Doherty (Ireland, Fine Gael/EPP)
Target audience	MEPs and political advisers, Commission officials, Member State officials, patient advocates, clinicians, researchers, professional societies and industry
Organiser	European Chronic Lymphocytic Leukaemia Association (ECLLA), supported by BeOne Medicines

The event will run for 90 minutes, opening with remarks from the host MEP, followed by ECLLA's launch of its European Policy Brief, two panel discussions, and closing remarks from the host MEP, then 30 minutes of networking.

About the event

This will be ECLLA's first event at EU level, taking place during Blood Cancer Awareness Month. The event aims to elevate blood cancers on the EU political agenda, expose geographic inequalities in diagnosis, treatment access, clinical trials and psychosocial support, and launch ECLLA's policy recommendations - built on four priorities: improving diagnosis and referral; equitable access to evidence-based care and treatment; expanding access to clinical trials and innovation; and integrating psychosocial support throughout the CLL pathway. The central policy question is: how can European and national action reduce inequalities in timely diagnosis, molecular testing, evidence-based treatment, clinical-trial access and lifelong support for every person living with Chronic Lymphocytic Leukaemia (CLL)?

Moderated by Catherine Hartmann

Time	Duration	Item	Speaker timings	Speakers
10:00 – 10:05	5 min	Welcome and political opening	10:00 – 10:05 (5 mins)	MEP Regina Doherty (EPP, IE) Host
10:05 – 10:15	10 min	Setting the scene: launch of ECLLA's European Policy Brief	10:05 – 10:15 (10 mins)	Jan Rynne Co-Founder & Association Development Lead, European CLL Association Victoria Hedley Rare Disease Policy Manager, Newcastle University and co-lead of the Newcastle Centre for Rare Disease
10:15 – 10:50	35 min	Panel 1 <i>Diagnosis, referral and equitable access to care</i>	10:15 – 10:24 (9 mins)	Amjad Hayat Clinical expert, Consultant Haematologist, University Hospital Galway

Time	Duration	Item	Speaker timings	Speakers
			10:24 – 10:33 (9 mins)	Eduardo Pisani CEO, All.Can
			10:33 – 10:42 (9 mins)	EU institutions representative Speaker TBC
			10:42 – 10:50 (8 mins)	Josephine Mosset Head of Policy, Cancer Patients Europe (CPE), Civil society representative
10:50 – 11:25	35 min	Panel 2 <i>Clinical trials, innovation and life beyond diagnosis</i>	10:50 – 10:59 (9 mins)	Peter Loffelhardt Advocate for MPN Patients, Founder of Global MPN Scientific Foundation
			10:59 – 11:08 (9 mins)	Amy Nolan CEO, ARC Cancer Support Centre and former Irish Cancer Society
			11:08 – 11:16 (8 mins)	Ivana Cattaneo Head of European Government Affairs and Public Policy, BeOne Medicines
			11:16 – 11:25 (8 mins)	NGO representative Speaker TBC
11:25 – 11:30	5 min	Political closing	11:25 – 11:30 (5 mins)	MEP - TBC
11:30 – 12:00	30 min	Q&A and Networking		Moderated by Catherine Hartmann